OMADA HEALTH INC (OMDA) Forecast, Price Target & Analyst Ratings

NASDAQ:OMDA • US68170A1088

13.51 USD

-0.42 (-3.02%)

At close: Mar 20, 2026

13.51 USD

0 (0%)

After Hours: 3/20/2026, 8:15:31 PM

View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for OMADA HEALTH INC (OMDA).

Consensus Price Target

Price Target

$27.08

+ 100.42% Upside

→ Price target details

Next Earnings Forecast

Earnings Estimate

Release Date: N/A
Period: Q1 / 2026
EPS Estimate: -$0.09
Revenue Estimate: 75.571M

→ Full earnings forecast details

ChartMill Buy Consensus

Rating

78.82%

Weighted Analyst Rating Score

→ Analyst Ratings details

Price Target Details & History

Consensus Price Target and Range

Mean target

$27.08

Upside

+ 100.42%

From current price of $13.51 to mean target of $27.08, Based on 17 analyst forecasts

Low

$17.17

Median

$28.56

High

$33.60

Price Target Revisions

1 Month

0.00%

3 Months

-8.15%

Price Target Summary

17 Wall Street analysts provided a forecast for the next 12 months for OMDA. The average price target is 27.08 USD. This implies a price increase of 100.42% is expected in the next year compared to the current price of 13.51.

The average price target has been revised downward by 8.15% in the past 3 months.

→ Find peer stocks trading 30% below analyst price target

Analyst Ratings & History

Current Analyst Ratings

Analyst Ratings History

Analyst Ratings Consensus

ChartMill Buy Consensus

78.82%

OMDA was analyzed by 17 analysts. The buy percentage consensus is at 79. So analysts seem to be have mildly positive about OMDA.

In the previous month the buy percentage consensus was at a similar level.

OMDA was analyzed by 17 analysts, which should be a sufficient number of analysts to have a meaningful average consensus rating.

→ Find peer stocks with a buy consensus above 85%

Recent Upgrades & Downgrades

Date	Firm	Action	From → To
2026-03-12	JP Morgan	Maintains	Overweight -> Overweight
2026-03-06	BMO Capital	Maintains	Outperform -> Outperform
2026-03-06	Barclays	Maintains	Overweight -> Overweight
2026-03-06	Canaccord Genuity	Maintains	Buy -> Buy
2026-03-06	Morgan Stanley	Maintains	Overweight -> Overweight
2026-03-03	Barclays	Maintains	Overweight -> Overweight
2026-01-22	Needham	Reiterate	Buy -> Buy
2026-01-09	Wells Fargo	Initiate	Equal-Weight
2026-01-05	Barclays	Maintains	Overweight -> Overweight
2025-11-13	BMO Capital	Initiate	Outperform
2025-11-07	Needham	Maintains	Buy -> Buy
2025-11-07	Barclays	Maintains	Overweight -> Overweight
2025-11-07	Evercore ISI Group	Maintains	Outperform -> Outperform
2025-10-22	Barclays	Maintains	Overweight -> Overweight
2025-09-05	Baird	Initiate	Neutral
2025-08-08	Needham	Maintains	Buy -> Buy
2025-08-08	Barclays	Maintains	Overweight -> Overweight
2025-08-08	Canaccord Genuity	Maintains	Buy -> Buy
2025-07-09	Evercore ISI Group	Maintains	Outperform -> Outperform
2025-07-01	Needham	Initiate	Buy
2025-07-01	Barclays	Initiate	Overweight
2025-07-01	JP Morgan	Initiate	Overweight
2025-07-01	Canaccord Genuity	Initiate	Buy
2025-07-01	Goldman Sachs	Initiate	Buy
2025-07-01	Morgan Stanley	Initiate	Overweight

Next Earnings Forecast Details

Next Earnings Details

Release Date: N/A
Period: Q1 / 2026
EPS Estimate: -$0.09
Revenue Estimate: 75.571M
Revenue Q2Q: 37.49%
EPS Q2Q: N/A
Number of Analysts: 11

Next Earnings Revisions

Revenue (1 Month)

3.64%

Revenue (3 Months)

4.64%

EPS (1 Month)

6.67%

EPS (3 Months)

1.18%

Next Earnings Summary

The next earnings revenue estimate has been revised upward by 4.64% in the past 3 months.

→ Find peers expecting at least 20% revenue growth next quarter

Full Analyst Estimates

Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates

	2023	2024	2025	2026	2027	2028
Revenue YoY % growth	122.784M 37.67%	169.8M 38.29%	260.21M 53.24%	325.1M 24.94%	390.71M 20.18%	462.33M 18.33%
EBITDA YoY % growth	-61.549M 9.51%	-38.851M 36.88%	-6.481M 83.32%	4.31M 166.50%	15.941M 269.86%	29.682M 86.20%
EBIT YoY % growth	-65.997M 8.78%	-43.654M 33.85%	-11.972M 72.58%	-10.326M 13.75%	6.18M 159.85%	33.285M 438.59%
Operating Margin	-53.75%	-25.71%	-4.60%	-3.18%	1.58%	7.20%
EPS YoY % growth	N/A	N/A	N/A	-0.07 74.78%	0.21 423.94%	0.48 125.15%

All data in USD

Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates

	Q1 / 26	Q2 / 26	Q3 / 26	Q4 / 26
EPS Q2Q % growth	-0.09	-0.02 90.08%	0.01 114.16%	0.01 -87.25%
Revenue Q2Q % growth	75.571M 37.49%	76.902M 25.31%	82.532M 21.32%	83.296M 9.82%
EBITDA Q2Q % growth	-2.875M 59.29%	403.196K 124.30%	2.955M 93.01%	4.283M -51.17%
EBIT Q2Q % growth	-6.789M 19.14%	-3.421M 21.26%	-1.382M 45.01%	-1.451M -144.24%

All data in USD

Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data

Long Term Forward Growth Forecast Summary

Long Term EPS Growth (CAGR)

EPS Next 3 Year

56.58%

EPS Next 5 Year

N/A

Long Term Revenue Growth (CAGR)

Revenue Next 3 Year

21.32%

Revenue Next 5 Year

N/A

Long Term EBIT Growth (CAGR)

EBIT Next 3 Year

58.32%

EBIT Next 5 Year

N/A

→ Find peers expecting at least 20% CAGR revenue growth over the next 3 years

OMADA HEALTH INC / OMDA Forecast FAQ

Can you provide the average price target for OMADA HEALTH INC stock?

17 analysts have analysed OMDA and the average price target is 27.08 USD. This implies a price increase of 100.42% is expected in the next year compared to the current price of 13.51.

Can you provide the consensus estimates for OMADA HEALTH INC next earnings?

The consensus EPS estimate for the next earnings of OMADA HEALTH INC (OMDA) is -0.09 USD and the consensus revenue estimate is 75.57M USD.

What is the consensus rating for OMDA stock?

The consensus rating for OMADA HEALTH INC (OMDA) is 78.8235 / 100 . This indicates that analysts generally have a positive outlook on the stock.

Analyst forecast overview

Forecast Snapshot